The pharmaceutical company Oasmia's share is, as of today, Thursday June 24, 2010, traded on NASDAQ OMX Stockholm's main stock list. The share has the same designation as before and shareholders need not take any actions. The move to the Stockholm stock exchange is a major milestone in the development of the company and is a natural effect of a series of positive news presented by the company in the last six months. For instance, Oasmia has closed a license and distribution agreement for the Japanese veterinary market and reported positive preliminary results from the Phase III study with the veterinary product Paccal® Vet. - We find it very exciting to now be on the Stockholm stock exchange main list. In addition to increased confidence for the company, this means that more investors now has the opportunity to invest in Swedish pharmaceutical development, says Oasmia's CEO, Julian Aleksov. In connection to the listing, Oasmia has published a prospectus which is available on the company website, www.oasmia.com. About Oasmia Oasmia Pharmaceutical AB develops second and third generation cancer drugs based on nanotechnology for human and veterinary use. The broad portfolio is focused on oncology and contains several promising products in clinical and pre-clinical phase. Oasmia cooperates with leading universities and other biotech companies to discover and optimize substances with a favorable safety profile and better efficacy. The company name was registered in 1999 and is based in Uppsala, Sweden. Follow us on Facebook and Twitter. For more information, please contact: Maria Lundén, Head of Public Relations, Oasmia Pharmaceutical AB E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. Information is also available at www.ngm.se and www.oasmia.com Follow us on Twitter and Facebook
The Oasmia Pharmaceutical share is now traded on NASDAQ OMX Stockholm
| Source: Oasmia Pharmaceutical AB
Attachments
